PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Abbeville, France, 80142
-
Agen, France, 47000
-
Aix En Provence, France, 13616
-
Aix En Provence, France, 13617
-
Amiens, France, 80090
-
Angers, France, 49933
-
Antibes, France, 06600
-
Armentieres, France, 59421
-
Aulnay Sous Bois, France, 93602
-
Bar Le Duc, France, 55012
-
Bayonne, France, 64100
-
Beuvry, France, 62660
-
Bordeaux, France, 33000
-
Boulogne-billancourt, France, 92100
-
Bourg En Bresse, France, 01012
-
Brive La Gaillarde, France, 19312
-
Bron, France, 69677
-
Bry Sur Marne, France, 94366
-
Carcassonne, France, 11890
-
Castres, France, 81108
-
Chalon Sur Saone, France, 71100
-
Chambery, France, 73011
-
Charleville Mezieres, France, 08011
-
Chaumont, France, 52014
-
Chauny, France, 02303
-
Clamart, France, 92141
-
Clermont-ferrand, France, 63003
-
Colmar, France, 68024
-
Compiegne, France, 60321
-
Creteil, France, 94010
-
Dijon, France, 21000
-
Dijon, France, 21079
-
Draguignan, France, 83007
-
Dunkerque, France, 59240
-
Epernay, France, 51205
-
Ermont, France, 95120
-
Ferolles Attilly, France, 77150
-
Forbach, France, 57604
-
GAP, France, 05007
-
Gleize, France, 69400
-
Gonesse, France, 95503
-
La Rochelle, France, 17019
-
La Source, France, 45100
-
La Tronche, France, 38700
-
Lagny Sur Marne, France, 77405
-
Le Mans, France, 72037
-
Le Mans, France, 72015
-
Le Puy En Velay, France, 43012
-
Lille, France, 59037
-
Lille, France, 59042
-
Lille, France, 59000
-
Limoges, France, 87042
-
Lisieux, France, 14107
-
Longjumeau, France, 91161
-
Lorient, France, 56322
-
Lyon, France, 69365
-
Lyon, France, 69275
-
Manosque, France, 04101
-
Mantes La Jolie, France, 78200
-
Mareuil Les Meaux, France, 77100
-
Marseille, France, 13291
-
Meaux, France, 77104
-
Metz, France, 57038
-
Metz Tessy, France, 74370
-
Mont-de-marsan, France, 40024
-
Montpellier, France, 34070
-
Nancy, France, 54100
-
Nantes, France, 44202
-
Narbonne, France, 11780
-
Neuilly Sur Seine, France, 92200
-
Neuilly-sur-seine, France, 92200
-
Paris, France, 75970
-
Paris, France, 75908
-
Paris, France, 75475
-
Paris, France, 75231
-
Perpignan, France, 66046
-
Perpignan, France, 66000
-
Pierre Benite, France, 69495
-
Poitiers, France, 86021
-
Pontoise, France, 95300
-
Quimper, France, 29000
-
Rambouillet, France, 78514
-
Reims, France, 51100
-
Reims CEDEX, France, 51056
-
Rennes, France, 35033
-
Rouen, France, 76031
-
Rouen, France, 76000
-
Saint Jean, France, 31240
-
Saint Laurent Du Var, France, 06700
-
Saint Priest En Jarez, France, 42770
-
Saintes, France, 17108
-
St Die Des Vosges, France, 88187
-
St Dizier, France, 52115
-
St Omer, France, 62500
-
St Quentin, France, 02321
-
St-Priest-En-Jarez, France, 42271
-
Strasbourg, France, 67091
-
Strasbourg, France, 67010
-
Strasbourg, France, 67065
-
Strasbourg, France, 67000
-
Thionville, France, 57126
-
Thonon-les-bains, France, 74203
-
Toulon, France, 83056
-
Toulon, France, 83041
-
Toulouse, France, 31076
-
Tours, France, 37000
-
Valence, France, 26000
-
Vandoeuvre-les-nancy, France, 54511
-
Vannes, France, 56017
-
Venissieux, France, 69200
-
Verdun, France, 55107
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Histologically or cytologically confirmed advanced (Stage IIIB) or metastatic (Stage IV) squamous non-small cell lung cancer after failure of first-line platinum-based chemotherapy
- Patients for whom the treating physician has decided to initiate treatment with Tarceva
Exclusion Criteria:
- Mixed non-small cell and small-cell lung carcinoma or mixed squamous cell carcinoma with predominant adenocarcinoma component
- Current participation in a clinical trial evaluating an anticancer treatment
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival
Time Frame: 2 years
|
2 years
|
|
Safety: Incidence of adverse events
Time Frame: 2 years
|
2 years
|
|
Clinical/demographic patients characteristics at baseline
Time Frame: 2 years
|
2 years
|
|
Treatment schedules: Dose/duration/modifications/interruptions
Time Frame: 2 years
|
2 years
|
|
Quality of life: FACT-L version 4 questionnaire
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML28195
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.